

Expected R&D Milestones

Products	Expected milestones	Timing
Dupixent®	Start of Phase 3 trial in Atopic Dermatitis in 6-11 year-olds	Q3 2017
Fluzone QIV HD	Start of Phase 3 trial	Q3 2017
VaxiGrip® QIV IM (6-35 months)	EU regulatory submission	Q3 2017
patisiran	Phase 3 results in Hereditary ATTR amyloidosis	Q3 2017
dupilumab	Phase 3 results in Asthma in Adult/Adolescent patients	Q4 2017
dupilumab	U.S. regulatory submission in Asthma in Adult/Adolescent patients	Q4 2017
Dupixent®	Start of Phase 3 trial in Atopic Dermatitis in 6 months to 5 year-olds	Q4 2017
efpeglenatide	Start of Phase 3 trial in type-2 Diabetes	Q4 2017
sotagliflozin	Start of Phase 3 trials in combination therapies in type-2 Diabetes	H2 2017
isatuximab	Start of additional Phase 3 trials in Multiple Myeloma and additional indications	H2 2017
SAR439684 (PD-1)	Phase 2/3 to start in additional solid tumors	H2 2017
Praluent®	ODYSSEY OUTCOMES top-line results	Q1 2018
SAR439684 (PD-1)	Phase 2 (registration) results in Cutaneous Squamous Cell Carcinoma	Q1 2018
GZ402668 (anti-CD52 mAb)	Start of Phase 3 in Relapsing Multiple Sclerosis	Q1 2018
dupilumab	Start of Phase 3 trial in Eosinophilic Esophagitis	Q1 2018
dupilumab	EU regulatory submission in Asthma in Adult/Adolescent patients	Q1 2018